Lighthouse Pharmaceuticals Secures $49.2M NIH Grant for Novel Alzheimer's Treatment Targeting Bacterial Driver
核心洞察
Lighthouse Pharmaceuticals (搜索) received a $49.2 million grant from the National Institute on Aging to conduct the Phase 2 SPRING trial of LHP588, a next-generation gingipain (搜索) inhibitor for P. gingivalis (搜索)-positive Alzheimer's disease (搜索).
The trial builds on previous GAIN trial results showing that gingipain (搜索) inhibition slowed cognitive decline in mild-moderate Alzheimer's patients with P. gingivalis (搜索) detected in saliva.
LHP588 represents a second-generation compound designed to overcome limitations of earlier molecules, offering improved safety and target engagement with once-daily oral dosing.
Lighthouse Pharmaceuticals (搜索) has secured a substantial $49.2 million grant from the National Institute on Aging (NIA) to advance its Phase 2 SPRING trial of LHP588, a novel gingipain (搜索) inhibitor targeting P. gingivalis (搜索)-positive Alzheimer's disease (搜索). The clinical-stage biopharmaceutical company will present trial data at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference in San Diego on December 3, 2025.
Targeting Bacterial Drivers of Alzheimer's Disease
The SPRING trial (Stopping PRogression of P. gINGivalis (搜索)-Positive AD with Gingipain (搜索) Inhibition) represents a precision medicine approach to Alzheimer's treatment, focusing specifically on patients with P. gingivalis detected in their saliva. This biomarker-guided strategy builds upon findings from the previous GAIN trial of atuzaginstat, which demonstrated that gingipain inhibitor treatment slowed cognitive decline in mild-moderate Alzheimer's patients positive for P. gingivalis.
"LHP588 represents a significant advancement in our effort to target a bacterial driver of Alzheimer's disease (搜索) with a high-precision oral medication," said Michael Detke, MD, PhD, Chief Medical Officer at Lighthouse Pharmaceuticals (搜索). "By focusing on P. gingivalis (搜索)–positive patients and integrating biomarker-guided selection we can maximize the benefit to patients with mild-moderate AD, for which there are no other disease-modifying therapies."
Second-Generation Compound Improvements
LHP588 was specifically developed to overcome limitations identified in the earlier atuzaginstat molecule. The second-generation compound offers improved safety and target engagement profiles while providing the convenience of once-daily oral dosing. This represents a significant advancement in the company's approach to targeting what they describe as a bacterial driver of Alzheimer's disease (搜索).
Expanding Clinical Reach
The ongoing Phase 2 SPRING trial (NCT06847321) is designed to evaluate the efficacy and safety of LHP588 in treating mild to moderate Alzheimer's disease (搜索) patients who test positive for P. gingivalis (搜索). Lighthouse Pharmaceuticals (搜索) plans to expand patient enrollment across the United States throughout 2026, addressing a patient population that currently lacks disease-modifying therapeutic options.
The substantial NIH funding underscores the scientific community's recognition of this novel mechanism of action in Alzheimer's treatment. The research is supported by the National Institute on Aging under Award Number R01AG088524, highlighting the federal government's investment in innovative approaches to neurodegenerative disease treatment.
Lighthouse Pharmaceuticals (搜索) specializes in developing small-molecule therapeutics for chronic degenerative and inflammatory disorders, with Alzheimer's disease (搜索) representing their lead clinical program. The company's approach leverages translational insights and extensive clinical experience to address major unmet medical needs in precision medicine.